Home    Back

 218. Alport syndrome
 [ 8 clinical trials,    15 drugs(DrugBank: 8 drugs),    5 target genes / 25 target pathways

Searched query = "Alport syndrome"
The queries were searched in Public_title, Scientific_title, and Condition of the data. Export date: 11/21/2019, 11/20/2019. Trials are sorted by Date_enrolment from most recent to oldest in the table.

Search in Page    e.g. "Phase 3", "Not recruiting", "Japan"
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03749447March 8, 20192 September 2019An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE)An Extended Access Program to Assess Long Term Safety of Bardoxolone Methyl in Patients With Chronic Kidney DiseaseChronic Kidney Diseases;Alport SyndromeDrug: Bardoxolone methylReata Pharmaceuticals, Inc.Recruiting12 Years65 YearsAll180Phase 3United States
2JPRN-UMIN0000324482018/05/017 October 2019A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport SyndromeA Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients with Alport Syndrome - CARDINALAlport SyndromeDrug: Bardoxolone Methyl
Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status. Dosing period is up to 2 years.
Drug: Placebo Oral Capsule
Capsule containing an inert placebo is administrated up to 2 years.
Reata Pharmaceuticals, IncNot Recruiting12years-old70years-oldMale and Female180Not selectedJapan,North America,Australia,Europe
3NCT03373786December 22, 20173 June 2019A Study of RG-012 in Subjects With Alport SyndromeA Phase 1, Open-Label Study to Evaluate the Safety, Pharmacodynamics, and Pharmacokinetics of RG-012 for Injection, Including Its Effect on Renal microRNA-21, in Subjects With Alport SyndromeAlport SyndromeDrug: RG012Genzyme, a Sanofi CompanyNot recruiting18 Years65 YearsAll4Phase 1United States
4NCT02855268November 7, 201711 November 2019Study of SAR339375 in Patients With Alport SyndromeA Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of SAR339375 for Subcutaneous Injection Administered Every Week in Patients With Alport SyndromeAlport's SyndromeDrug: SAR339375;Drug: PlaceboGenzyme, a Sanofi CompanyRecruiting18 Years55 YearsAll45Phase 2United States
5NCT03019185March 2, 201726 November 2018A Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport Syndrome - CARDINALA Phase 2/3 Trial of the Efficacy and Safety of Bardoxolone Methyl in Patients With Alport SyndromeAlport SyndromeDrug: Placebo Oral Capsule;Drug: Bardoxolone MethylReata Pharmaceuticals, Inc.Not recruiting12 Years60 YearsAll187Phase 2/Phase 3United States;Australia;France;Germany;Japan;Puerto Rico;Spain;United Kingdom;Canada
No.TrialIDDate_
enrollement
Last_Refreshed_
on
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
6NCT01485978March 201216 December 2017Efficacy and Safety Study to Delay Renal Failure in Children With Alport SyndromeEarly Prospective Therapy Trial to Delay Renal Failure in Children With Alport SyndromeRenal Insufficiency, ChronicDrug: Ramipril;Drug: placebo to ramiprilInstitut fuer anwendungsorientierte Forschung und klinische Studien GmbHUniversity Medical Center Goettingen;German Federal Ministry of Education and ResearchNot recruiting24 Months18 YearsAll66Phase 3Germany
7NCT00309257January 200419 February 2015Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport SyndromeEffects of an Intensified Treatment With ACE-inhibitors, Angiotensin II Receptor Antagonists and Statins in Alport SyndromeAlport SyndromeDrug: ACE I, ATA II and Statins;Drug: Benazepril, Valsartan and FluvastatinMario Negri Institute for Pharmacological ResearchNot recruiting15 Years70 YearsBoth9Phase 2Italy
8NCT02378805July 199511 February 2019European Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport SyndromeEuropean Alport Therapy Registry - European Initiative Towards Delaying Renal Failure in Alport Syndrome: Current and Novel TherapiesAlport Syndrome;Hereditary Kidney Disease;Pediatric Kidney Disease;Thin Basement Membrane Disease;Familial Benign HematuriaDrug: ACE-inhibitor;Drug: AT1-inhibitor;Drug: HMG-Coenzyme inhibitor (statin);Drug: Spironolactone;Drug: ParicalcitolUniversity Hospital GoettingenSociety for Pediatric Nephrology (Germany);Deutsche Gesellschaft für Nephrologie;Alport Selbsthilfe e.V.;Association pour l'Information et la Recherche sur les Maladies Rénales Génétiques (AIRG);KfH Foundation Preventive MedicineRecruitingN/AN/AAll500N/AGermany

Back to top